| The war on cancer has a birthday, and a present |
| VT DeVita, Jr |
|
JCO Mar 1 1997: 867–869.
[PDF]
|
 |
| Decision analysis in non-small-cell lung cancer: not back to the drawing modeling board, back to the bedside |
| TJ Smith, BE Hillner, and RB Mitchell |
|
JCO Mar 1 1997: 870–872.
[PDF]
|
|
|
Decision analysis in locally advanced non-small-cell lung cancer: is it useful? |
| |
MD Brundage, PA Groome, D Feldman-Stewart, JR Davidson, and WJ Mackillop |
| |
JCO Mar 1 1997: 873–883.
[Abstract]
[PDF]
|
|
|
Phase I study of vinorelbine and ifosfamide in advanced non-small-cell lung cancer |
| |
GA Masters, PC Hoffman, A Hsieh, LC Drinkard, R Mick, BL Samuels, A Guaspari, HM Golomb, and EE Vokes |
| |
JCO Mar 1 1997: 884–892.
[Abstract]
[PDF]
|
|
|
Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study |
| |
B Jeremic, Y Shibamoto, L Acimovic, and S Milisavljevic |
| |
JCO Mar 1 1997: 893–900.
[Abstract]
[PDF]
|
|
|
Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study |
| |
H Safran, TP King, H Choy, PJ Hesketh, B Wolf, E Altenhein, W Sikov, A Rosmarin, W Akerley, K Radie-Keane, G Cicchetti, F Lopez, K Bland, and HJ Wanebo |
| |
JCO Mar 1 1997: 901–907.
[Abstract]
[PDF]
|
|
|
Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study |
| |
W Scheithauer, G Kornek, A Marczell, G Salem, J Karner, E Kovats, D Burger, R Greiner, J Pidlich, B Schneeweiss, M Raderer, H Rosen, and D Depisch |
| |
JCO Mar 1 1997: 908–914.
[Abstract]
[PDF]
|
|
|
Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer |
| |
CD Blanke, B Kasimis, P Schein, R Capizzi, and M Kurman |
| |
JCO Mar 1 1997: 915–920.
[Abstract]
[PDF]
|
|
|
Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer |
| |
K Shirao, Y Shimada, H Kondo, D Saito, T Yamao, H Ono, T Yokoyama, H Fukuda, M Oka, Y Watanabe, A Ohtsu, N Boku, T Fujii, Y Oda, K Muro, and S Yoshida |
| |
JCO Mar 1 1997: 921–927.
[Abstract]
[PDF]
|
|
|
Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas |
| |
FR Spitz, JL Abbruzzese, JE Lee, PW Pisters, AM Lowy, CJ Fenoglio, KR Cleary, NA Janjan, MS Goswitz, TA Rich, and DB Evans |
| |
JCO Mar 1 1997: 928–937.
[Abstract]
[PDF]
|
|
|
Liver resection for colorectal metastases |
| |
Y Fong, AM Cohen, JG Fortner, WE Enker, AD Turnbull, DG Coit, AM Marrero, M Prasad, LH Blumgart, and MF Brennan |
| |
JCO Mar 1 1997: 938–946.
[Abstract]
[PDF]
|
|
|
Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors |
| |
J Klempnauer, GJ Ridder, R von Wasielewski, M Werner, A Weimann, and R Pichlmayr |
| |
JCO Mar 1 1997: 947–954.
[Abstract]
[PDF]
|
|
|
Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo- controlled study |
| |
PD Delmas, R Balena, E Confravreux, C Hardouin, P Hardy, and A Bremond |
| |
JCO Mar 1 1997: 955–962.
[Abstract]
[PDF]
|
|
|
Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France |
| |
P Romestaing, Y Lehingue, C Carrie, R Coquard, X Montbarbon, JM Ardiet, N Mamelle, and JP Gerard |
| |
JCO Mar 1 1997: 963–968.
[Abstract]
[PDF]
|
|
|
Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer |
| |
CL Loprinzi, S Abu-Ghazaleh, JA Sloan, C vanHaelst-Pisani, AM Hammer, KM Rowland, Jr, M Law, HE Windschitl, JS Kaur, and N Ellison |
| |
JCO Mar 1 1997: 969–973.
[Abstract]
[PDF]
|
|
|
Reliability and validity of the Functional Assessment of Cancer Therapy- Breast quality-of-life instrument |
| |
MJ Brady, DF Cella, F Mo, AE Bonomi, DS Tulsky, SR Lloyd, S Deasy, M Cobleigh, and G Shiomoto |
| |
JCO Mar 1 1997: 974–986.
[Abstract]
[PDF]
|
|
|
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation |
| |
FM Muggia, JD Hainsworth, S Jeffers, P Miller, S Groshen, M Tan, L Roman, B Uziely, L Muderspach, A Garcia, A Burnett, FA Greco, CP Morrow, LJ Paradiso, and LJ Liang |
| |
JCO Mar 1 1997: 987–993.
[Abstract]
[PDF]
|
|
|
Surgical second look in ovarian cancer: a randomized study in patients with laparoscopic complete remission--a Northeastern Oncology Cooperative Group-Ovarian Cancer Cooperative Group Study |
| |
MO Nicoletto, S Tumolo, R Talamini, L Salvagno, S Franceschi, E Visona, G Marin, F Angelini, G Brigato, C Scarabelli, A Carbone, A Cecchetto, A Prosperi, A Rosabian, M Giusto, GP Cima, S Morassut, O Nascimben, O Vinante, and MV Fiorentino |
| |
JCO Mar 1 1997: 994–999.
[Abstract]
[PDF]
|
|
|
Resource implications of palliative chemotherapy for ovarian cancer |
| |
C Doyle, M Stockler, M Pintilie, P Panesar, P Warde, J Sturgeon, and AM Oza |
| |
JCO Mar 1 1997: 1000–1007.
[Abstract]
[PDF]
|
|
|
Detection of human papillomavirus mRNA and cervical cancer cells in peripheral blood of cervical cancer patients with metastasis |
| |
CC Pao, JJ Hor, FP Yang, CY Lin, and CJ Tseng |
| |
JCO Mar 1 1997: 1008–1012.
[Abstract]
[PDF]
|
|
|
Phase III trial of androgen suppression using goserelin in unfavorable- prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31 |
| |
MV Pilepich, R Caplan, RW Byhardt, CA Lawton, MJ Gallagher, JB Mesic, GE Hanks, CT Coughlin, A Porter, WU Shipley, and D Grignon |
| |
JCO Mar 1 1997: 1013–1021.
[Abstract]
[PDF]
|
|
|
Bladder preservation by combined modality therapy for invasive bladder cancer |
| |
LA Kachnic, DS Kaufman, NM Heney, AF Althausen, PP Griffin, AL Zietman, and WU Shipley |
| |
JCO Mar 1 1997: 1022–1029.
[Abstract]
[PDF]
|
|
|
Markers of radioresistance in squamous cell carcinomas of the head and neck: a clinicopathologic and immunohistochemical study |
| |
H Raybaud-Diogene, A Fortin, R Morency, J Roy, RA Monteil, and B Tetu |
| |
JCO Mar 1 1997: 1030–1038.
[Abstract]
[PDF]
|
|
|
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system |
| |
AC Buzaid, MI Ross, CM Balch, S Soong, WH McCarthy, L Tinoco, P Mansfield, JE Lee, A Bedikian, O Eton, C Plager, N Papadopoulos, SS Legha, and RS Benjamin |
| |
JCO Mar 1 1997: 1039–1051.
[Abstract]
[PDF]
|
|
|
Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma |
| |
JS Du Bois, EG Trehu, JW Mier, L Shapiro, M Epstein, M Klempner, C Dinarello, K Kappler, L Ronayne, W Rand, and MB Atkins |
| |
JCO Mar 1 1997: 1052–1062.
[Abstract]
[PDF]
|
|
|
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors |
| |
SE Kaba, AP Kyritsis, K Hess, WK Yung, R Mercier, S Dakhil, KA Jaeckle, and VA Levin |
| |
JCO Mar 1 1997: 1063–1070.
[Abstract]
[PDF]
|
|
|
Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors |
| |
LC Pronk, JH Schellens, AS Planting, MJ van den Bent, PH Hilkens, ME van der Burg, M de Boer-Dennert, J Ma, C Blanc, M Harteveld, R Bruno, G Stoter, and J Verweij |
| |
JCO Mar 1 1997: 1071–1079.
[Abstract]
[PDF]
|
|
|
High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study |
| |
Y Merrouche, JM Extra, D Abigerges, R Bugat, G Catimel, E Suc, M Marty, P Herait, M Mahjoubi, and JP Armand |
| |
JCO Mar 1 1997: 1080–1086.
[Abstract]
[PDF]
|
|
|
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors |
| |
GJ Creemers, CJ Gerrits, JR Eckardt, JH Schellens, HA Burris, AS Planting, GI Rodriguez, WJ Loos, I Hudson, C Broom, J Verweij, and DD Von Hoff |
| |
JCO Mar 1 1997: 1087–1093.
[Abstract]
[PDF]
|
|
|
Mitoguazone therapy in patients with refractory or relapsed AIDS- related lymphoma: results from a multicenter phase II trial |
| |
AM Levine, A Tulpule, D Tessman, L Kaplan, F Giles, BD Luskey, DT Scadden, DW Northfelt, I Silverberg, J Wernz, B Espina, and D Von Hoff |
| |
JCO Mar 1 1997: 1094–1103.
[Abstract]
[PDF]
|
|
|
Is the polymerase chain reaction or cure of Helicobacter pylori infection of help in the differential diagnosis of early gastric mucosa- associated lymphatic tissue lymphoma? |
| |
B Rudolph, E Bayerdorffer, M Ritter, S Muller, C Thiede, B Neubauer, N Lehn, E Seifert, P Otto, R Hatz, M Stolte, and A Neubauer |
| |
JCO Mar 1 1997: 1104–1109.
[Abstract]
[PDF]
|
|
|
Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte |
| |
P Brice, Y Bastion, E Lepage, N Brousse, C Haioun, P Moreau, N Straetmans, H Tilly, I Tabah, and P Solal-Celigny |
| |
JCO Mar 1 1997: 1110–1117.
[Abstract]
[PDF]
|
|
|
Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: a pilot study |
| |
A Rueda, E Alba, N Ribelles, I Sevilla, I Ruiz, and J Miramon |
| |
JCO Mar 1 1997: 1118–1122.
[Abstract]
[PDF]
|
|
|
Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies |
| |
MJ Torrey, JC Poen, and RT Hoppe |
| |
JCO Mar 1 1997: 1123–1130.
[Abstract]
[PDF]
|
|
|
Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte |
| |
C Haioun, E Lepage, C Gisselbrecht, Y Bastion, B Coiffier, P Brice, A Bosly, B Dupriez, C Nouvel, H Tilly, P Lederlin, P Biron, J Briere, P Gaulard, and F Reyes |
| |
JCO Mar 1 1997: 1131–1137.
[Abstract]
[PDF]
|
|
|
Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up |
| |
MA Hoffman, D Janson, E Rose, and KR Rai |
| |
JCO Mar 1 1997: 1138–1142.
[Abstract]
[PDF]
|
|
|
Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL |
| |
KD Heckman, GJ Weiner, CS Davis, RG Strauss, MP Jones, and CP Burns |
| |
JCO Mar 1 1997: 1143–1149.
[Abstract]
[PDF]
|
|
|
TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance |
| |
JE Rubnitz, JR Downing, CH Pui, SA Shurtleff, SC Raimondi, WE Evans, DR Head, WM Crist, GK Rivera, ML Hancock, JM Boyett, A Buijs, G Grosveld, and FG Behm |
| |
JCO Mar 1 1997: 1150–1157.
[Abstract]
[PDF]
|
|
|
Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia |
| |
DI Marks, BW Kurz, MP Link, E Ng, JJ Shuster, SJ Lauer, D Carroll, I Brodsky, and DS Haines |
| |
JCO Mar 1 1997: 1158–1162.
[Abstract]
[PDF]
|
|
|
Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients |
| |
PL Mitchell, B Morland, MC Stevens, G Dick, D Easlea, LC Meyer, and CR Pinkerton |
| |
JCO Mar 1 1997: 1163–1170.
[Abstract]
[PDF]
|
|
|
N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique |
| |
H Rubie, O Hartmann, J Michon, D Frappaz, C Coze, P Chastagner, MC Baranzelli, D Plantaz, H Avet-Loiseau, J Benard, O Delattre, M Favrot, MC Peyroulet, A Thyss, Y Perel, C Bergeron, B Courbon-Collet, JP Vannier, J Lemerle, and D Sommelet |
| |
JCO Mar 1 1997: 1171–1182.
[Abstract]
[PDF]
|
|
|
Orbital development in long-term survivors of retinoblastoma |
| |
SC Kaste, G Chen, J Fontanesi, DB Crom, and CB Pratt |
| |
JCO Mar 1 1997: 1183–1189.
[Abstract]
[PDF]
|
|
|
Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children's Cancer Group |
| |
JM Van Tornout, JD Buckley, JJ Quinn, JH Feusner, MD Krailo, DR King, GD Hammond, and JA Ortega |
| |
JCO Mar 1 1997: 1190–1197.
[Abstract]
[PDF]
|
|
|
Clinical relevance of DNA ploidy and proliferative activity in childhood rhabdomyosarcoma: a retrospective analysis of patients enrolled onto the Italian Cooperative Rhabdomyosarcoma Study RMS88 |
| |
L De Zen, A Sommaggio, ES d'Amore, L Masiero, LC di Montezemolo, A Linari, E Madon, C Dominici, S Bosco, G Bisogno, M Carli, V Ninfo, and G Basso |
| |
JCO Mar 1 1997: 1198–1205.
[Abstract]
[PDF]
|
|
|
Value of caregiver ratings in evaluating the quality of life of patients with cancer |
| |
KC Sneeuw, NK Aaronson, MA Sprangers, SB Detmar, LD Wever, and JH Schornagel |
| |
JCO Mar 1 1997: 1206–1217.
[Abstract]
[PDF]
|
|
|
Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group |
| |
J Glaspy, R Bukowski, D Steinberg, C Taylor, S Tchekmedyian, and S Vadhan-Raj |
| |
JCO Mar 1 1997: 1218–1234.
[Abstract]
[PDF]
|
|
|
Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy |
| |
CL Loprinzi, C Ghosh, J Camoriano, J Sloan, PD Steen, JC Michalak, PL Schaefer, PJ Novotny, JB Gerstner, DF White, AK Hatfield, and SK Quella |
| |
JCO Mar 1 1997: 1235–1238.
[Abstract]
[PDF]
|
|
|
Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis |
| |
WL McGinnis, CL Loprinzi, SJ Buskirk, JA Sloan, RG Drummond, AR Frank, TG Shanahan, SP Kahanic, RL Moore, SE Schild, and SL Humphrey |
| |
JCO Mar 1 1997: 1239–1243.
[Abstract]
[PDF]
|
|
|
Functional vision is improved in the majority of patients treated with external-beam radiotherapy for choroid metastases: a multivariate analysis of 188 patients |
| |
SB Rudoler, CL Shields, BW Corn, P De Potter, T Hyslop, WJ Curran, Jr, and JA Shields |
| |
JCO Mar 1 1997: 1244–1251.
[Abstract]
[PDF]
|
|
|
Patient preferences concerning the trade-off between the risks and benefits of routine radiation therapy after conservative surgery for early-stage breast cancer |
| |
JA Hayman, DL Fairclough, JR Harris, and JC Weeks |
| |
JCO Mar 1 1997: 1252–1260.
[Abstract]
[PDF]
|
|
|
Does a centralized radiotherapy system provide adequate access to care? |
| |
WJ Mackillop, PA Groome, J Zhang-Solomons, Y Zhou, D Feldman-Stewart, L Paszat, P Dixon, EJ Holowaty, and BJ Cummings |
| |
JCO Mar 1 1997: 1261–1271.
[Abstract]
[PDF]
|
|
|
Paraneoplastic syndromes of gynecologic neoplasms |
| |
AA Ashour, CF Verschraegen, AP Kudelka, and JJ Kavanagh |
| |
JCO Mar 1 1997: 1272–1282.
[Abstract]
[PDF]
|
|
| AIDS-related Kaposi's sarcoma |
| MR van den Brink and BJ Dezube |
|
JCO Mar 1 1997: 1283–1284.
[PDF]
|
|
| Cytoreduction and prognosis in childhood acute lymphoblastic leukemia |
| M Arico and G Masera |
|
JCO Mar 1 1997: 1285a.
[PDF]
|
|
| The question remains: oncology and primary care |
| RF Holcombe |
|
JCO Mar 1 1997: 1285b–1286.
[PDF]
|
|
| Correction--malignant glioma |
| JO Atiba and FL Meyskens, Jr |
|
JCO Mar 1 1997: 1286–1287.
[PDF]
|
|
| Chemotherapy-induced insulin-dependent diabetes mellitus |
| A Dispenzieri and CL Loprinzi |
|
JCO Mar 1 1997: 1287.
[PDF]
|
|
